Evolving Strategies in the Management of HER2-Positive Early-Stage Breast Cancer

Evolving Strategies in the Management of HER2-Positive Early-Stage Breast Cancer

Evolving Strategies in the Management of HER2-Positive Early-Stage Breast Cancer
RestartResume

Learn about subcutaneous approaches for HER2-positive early-stage breast cancer and how they can reduce the burden of therapy for your patents.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Although outcomes have improved for women with HER2-positive early-stage breast cancer, patients who do not have a pathologic complete response after neoadjuvant therapy are at an increased risk for recurrence and need further improvements in therapy options.

    In this activity, Drs. Charles Geyer and Hope Rugo discuss how the management of HER2-positive early-stage breast cancer has evolved, the continued quest to reduce the burden of therapy on patients—and how subcutaneous approaches are achieving this—and other challenges in the treatment continuum.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Charles E. Geyer, Jr., MD, FACP
    Deputy Director, Cancer Center
    Houston Methodist
    Houston, TX 

    Consulting Fees: Athenex, Exact Sciences

    Faculty:
    Hope S. Rugo, MD
    Professor of Medicine
    University of California San Francisco Comprehensive Cancer Center
    San Francisco, CA

    Consulting Fees: Mylan, Puma, Samsung
    Contracted Research: AstraZeneca, Daiichi, Eisai, Genentech, Immunomedics, Lilly, Macrogenics, Merck, Novartis, OBI, Odonate, Pfizer, Seattle Genetics, Sermonix

    Reviewers/Content Planners/Authors:

    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest in Vertex Pharmaceuticals.
    • Colleen Resnick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize current management challenges in the neoadjuvant and adjuvant treatment settings for HER2-positive early-stage breast cancer.
    • Identify patient characteristics to help optimize treatment selections in the neoadjuvant and adjuvant settings for HER2-positive early-stage breast cancer.
    • Evaluate the advantages and disadvantages of the novel subcutaneous approaches to therapy for HER2-positive early-stage breast cancer.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, oncology nurse practitioners, physician assistants and registered nurses, pathologists, and ob-gyns.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free